September is Sepsis Awareness Month, a time to highlight one of the most critical threats to newborns: neonatal sepsis.
The Particular Danger of Neonatal Sepsis
Neonatal sepsis is especially dangerous due to its non-specific and subtle symptoms in newborns, which can delay diagnosis and treatment. Key signs include:
Lethargy, difficulty waking, or reduced activity
Poor feeding or vomiting
Temperature instability (fever or hypothermia)
Pale or mottled skin
Rapid or difficult breathing
Unusual crying or irritability
Because infants cannot verbalize their distress, sepsis can progress rapidly with devastating consequences, including:
Septic shock and multi-organ failure
Long-term neurological damage
Disability or growth impairment
High risk of mortality if not treated immediately
Group B Streptococcus (GBS) is a leading cause of neonatal sepsis. While typically harmless in healthy adults, GBS can be transmitted during childbirth and lead to severe
infections such as sepsis, pneumonia, and meningitis in infants.
Approximately 1 in 4 pregnant individuals carry GBS—often without symptoms—making routine screening essential. Traditional testing methods, however, face significant challenges:
Time Delays: Standard culture methods take 18-36 hours for results – time often unavailable when labor progresses quickly.
False Negatives: Culture sensitivity can drop significantly (studies suggest around 18.5% false negatives), partly due to recent antibiotic use masking growth.
Limited Point-of-Care Options: While faster immunoassays exist, they often lack sufficient sensitivity. Molecular tests offer accuracy but traditionally required specialized labs and took hours.
These delays can be critical during preterm labor or premature rupture of membranes (PROM), where timely intervention is vital.
Introducing the GBS+Easy Amp System – Rapid, Accurate, Point-of-Care Detection
The Macro & Micro-Test GBS+Easy Amp System revolutionizes GBS screening with:
Unprecedented Speed: Delivers positive results in just 5 minutes, enabling immediate clinical action.
High Accuracy: Molecular technology provides reliable results, minimizing dangerous false negatives.
True Point-of-Care: The Easy Amp System facilitates on-demand testing directly in labor & delivery or antenatal clinics using standard vaginal/rectal swabs.
Operational Flexibility: Independent system modules allow testing to adapt to clinical workflow needs.
This innovation ensures that carriers receive timely intrapartum antibiotic prophylaxis (IAP), significantly reducing the risk of neonatal GBS transmission and sepsis.
A Call to Action: Protect Newborns with Faster, Smarter Diagnostics
This Sepsis Awareness Month, join us in prioritizing rapid GBS screening to:
Save crucial minutes during high-risk deliveries
Reduce unnecessary antibiotic use
Improve outcomes for mothers and newborns
Together, we can ensure every newborn has the safest start in life.
For product and distribution details, contact us at marketing@mmtest.com.
Learn more: GBS+Easy Amp System
Post time: Sep-05-2025